A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs ASG 15ME (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma; Astellas Pharma Global Development
- 11 Nov 2019 Status changed from active, no longer recruiting to completed.
- 25 Feb 2019 Planned End Date changed from 1 Mar 2019 to 1 Jan 2020.
- 25 Feb 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Jan 2020.